Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.

@article{Werth2021RituximabVM,
  title={Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.},
  author={Victoria P. Werth and Pascal Joly and Daniel Mimouni and Emanual Maverakis and Fr{\'e}d{\'e}ric Caux and Patricia B. Lehane and L. Gearhart and Audrey Kapre and Pooneh Pordeli and Diana M. Chen},
  journal={The New England journal of medicine},
  year={2021}
}
BACKGROUND Rituximab and mycophenolate mofetil are used to treat pemphigus vulgaris, but they have not been adequately compared in clinical trials. METHODS In a randomized, controlled trial, we assigned patients with moderate-to-severe pemphigus vulgaris in a 1:1 ratio to receive intravenous rituximab (1000 mg on days 1, 15, 168, and 182) or oral mycophenolate mofetil (2 g per day), in addition to an oral glucocorticoid administered on the same tapering schedule in the two groups. The primary… 

Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris.

The favorable results of this study suggest that the high acquisition costs of rituximab biosimilars may be offset by its effectiveness and provide economic evidence in support of its listing on the Pharmaceutical Benefits Scheme for pemphigus vulgaris.

Immunotherapy for Pemphigus: Present and Future

The immune targets and corresponding agents applied in practice or under clinical trials are reviewed to improve the quality of life of pemphigus patients by improving efficacy and safety, minimizing side effects, achieving fast disease control, or curing the disease.

Pemphigus vulgaris relapse during the coronavirus disease pandemic

The treatments with systemic steroids, immunosuppressive drugs, and rituximab were well tolerated by the patients with relapsing PV, provided that there was no contact with individuals with COVID‐19.

Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature

The case of a 13‐year‐old male with PV treated successfully with systemic corticosteroids and rituximab is reported, and the literature supporting the treatment of pediatric PV with r ituximabs is reviewed.

Clinical Patterns, Survival, Comorbidities, and Treatment Regimens in 149 Patients With Pemphigus in Tuscany (Italy): A 12-Year Hospital-Based Study

In this large series of patients, patients with pemphigus showed a high incidence of serious comorbid diseases, highlighting the importance of a multidisciplinary approach for a proper management of the patients.

Burden of pemphigus vulgaris with a particular focus on women: A review

The burden of pemphigus vulgaris on various aspects of women’s lives is summarized and it is essential to understand these problems and provide appropriate support for patients with such a burdensome disease.

Prominent B cell signature differentiates discoid from subacute cutaneous lupus erythematosus.

FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus

The aim of this study was to assess the impact of FcRn antagonism by efgartigimod on immunological parameters known to be directly involved in pemphigus pathology, such as cellular and serological responses, and to establish long-term clinical responses in autoimmune diseases.

Journal Club Review of “Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody–Associated Vasculitis: Systematic Review and Meta‐Analysis”

The objective of this study was to compare the efficacy and safety of two rituximab (RTX) regimens for the induction of remission in severe antineutrophil cytoplasm antibody‐associated vasculitis

Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.